Economic assessment of different modalities of immunoglobulin replacement therapy.
The delivery (intravenous or subcutaneous), location (home or hospital), and other factors of immunoglobulin replacement therapy are examined for cost effectiveness. Cost-minimization studies from several countries are reviewed and analyzed. A Canadian cost-minimization study is performed. Although common themes emerge, there are cost differences between the various countries.
Membe
Stephen K
SK
Canadian Agency for Drugs and Technologies in Health (CADTH), 600-865 Carling Avenue, Ottawa, ON, Canada K1S 5S8.
Ho
Chuong
C
Cimon
Karen
K
Morrison
Andra
A
Kanani
Amin
A
Roifman
Chaim M
CM
D000328:Adult; D002170:Canada; D002675:Child, Preschool; D003363:Cost Control; D003362:Cost-Benefit Analysis; D016503:Drug Delivery Systems / Q000191:economics / Q000379:methods; D017048:Health Care Costs; D054625:Healthcare Disparities / Q000191:economics; D006801:Humans; D007116:Immunization, Passive / Q000191:economics* / Q000379:methods; D007153:Immunologic Deficiency Syndromes / Q000191:economics / Q000276:immunology / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic